RPE65 and Leber congenital amaurosis: The long-term sustained effects on safety and efficacy of AAV2-RPE65 gene delivery in biallelic RPE65-mediated LCA were assessed over a period of three years with the initial improvements in visual function peaking at 6–12 months after injection [163,164].